Ionis Pharmaceuticals, Inc. develops RNA-targeted medicines and reports news around marketed medicines and a pipeline in neurology, cardiometabolic disease and other high-need areas. Company updates commonly address commercial performance for TRYNGOLZA, financial results, R&D revenue from partnerships, and progress across antisense oligonucleotide programs.
Clinical and regulatory news also covers programs such as olezarsen for severe hypertriglyceridemia, zilganersen for Alexander disease, and partner-developed bepirovirsen for chronic hepatitis B. Governance and investor-relations releases include annual meeting materials, board composition changes, and healthcare conference presentations.
Ionis (NASDAQ: IONS) priced $700.0 million aggregate principal of 0.00% convertible senior notes due 2030, with an underwriter option for an additional $70.0 million. The offering is expected to close on November 17, 2025, with estimated net proceeds of approximately $682.8 million (or $751.2 million if the option is exercised).
Ionis expects to use about $267.6 million of net proceeds to repurchase $200.0 million aggregate principal of its 0% convertible notes due 2026 via concurrent repurchase transactions and the remainder for additional repurchases, repayment at maturity, and general corporate purposes. Initial conversion rate is 10.1932 shares per $1,000 (approx. $98.10 per share), a ~35.0% premium to the Nov 12, 2025 share price. Notes mature Dec 1, 2030 and are non‑interest bearing.
Ionis (Nasdaq: IONS) announced management will participate in investor fireside chats at two upcoming conferences: the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 and the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025.
A live webcast of both presentations will be available on the company's Investors & Media website and replays will be posted within 48 hours; replays will be archived for a limited time.
Ionis (NASDAQ: IONS) announced on November 11, 2025 a proposed private placement of $700.0 million aggregate principal amount of Convertible Senior Notes due 2030, with an initial purchaser option for up to an additional $70.0 million. The notes will be unsecured, pay interest semiannually, and on conversion may be settled in cash, shares, or a combination at Ionis’ election. The offering is to qualified institutional buyers under Rule 144A.
Use of proceeds: Ionis expects net proceeds to be used to repurchase or repay its 0% Convertible Senior Notes due 2026, including possible concurrent negotiated repurchases, with any remainder for general corporate purposes. Pricing, interest rate, and conversion rate will be determined at pricing.
Ionis (Nasdaq: IONS) reported positive pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia (sHTG) on November 8, 2025. In nearly 1,100 patients, olezarsen achieved up to a 72% placebo-adjusted mean reduction in fasting triglycerides at six months with sustained reductions to 12 months.
Key outcomes: 86% of treated patients reached TGs <500 mg/dL; adjudicated acute pancreatitis events fell by 85% (p<0.001); NNT=20 overall, NNT=4 in highest-risk subgroup. Data were presented at AHA and published in NEJM. Ionis plans an FDA supplemental NDA submission by year-end and will host a webcast Nov 8 at 3:00 p.m. ET.
Ionis (Nasdaq: IONS) announced long-term clinical data for DAWNZERA (donidalorsen) presented at ACAAI 2025 showing durable HAE control and a favorable safety profile.
Key results: in the OASISplus open-label extension at Week 52 DAWNZERA showed a 94% (Q4W, n=69) and 95% (Q8W, n=14) mean HAE attack rate reduction from baseline; the OASISplus switch cohort (n=64) achieved a 68% improvement versus prior prophylaxis at one year. Phase 2 OLE reported a 97% mean attack reduction over four years, median attack-free interval of 2.7 years, and 71% attack-free >1 year. Safety: most TEAEs were mild/moderate, no serious TEAEs related to DAWNZERA; hypersensitivity including anaphylaxis is a listed risk.
Ionis (Nasdaq: IONS) reported Q3 2025 results and program updates on October 29, 2025. Total revenue was $157M in Q3 (+17% YoY) and $740M year-to-date (+55% YoY). TRYNGOLZA net product sales were $32M in Q3 and $57M YTD; WAINUA sales generated $59M in Q3. The company raised full-year 2025 guidance to $875–900M revenue and increased TRYNGOLZA sales guidance to $85–95M. Non-GAAP operating loss guidance was tightened to $275–300M, and cash was confirmed at > $2.1B.
Clinical and regulatory highlights: olezarsen Phase 3 showed up to 72% triglyceride reduction and 85% reduction in acute pancreatitis events (sNDA on track by year-end); zilganersen met its pivotal endpoint (10MWT mean difference 33.3%) with NDA planned Q1 2026; DAWNZERA U.S. launch underway.
Ionis (Nasdaq: IONS) will present detailed Phase 3 results for olezarsen in severe hypertriglyceridemia (sHTG) as a late-breaking abstract at AHA Scientific Sessions on November 8, 2025. The CORE and CORE2 pivotal studies showed a highly statistically significant reduction in fasting triglycerides and fewer acute pancreatitis events, with reported favorable safety and tolerability. Ionis plans to submit a supplemental NDA to the U.S. FDA by the end of the year. The presentation (CORE-TIMI 72a and CORE2-TIMI 72b) is scheduled for 9:40–9:50 a.m. ET and a company webcast to discuss results will be held on November 8 at 3:00 p.m. ET, with a limited-time replay available.
Ionis (Nasdaq: IONS) was ranked #2 in Science magazine’s 2025 Top Employer survey, marking the company’s first year of eligibility for the list.
The ranking cited industry-leading innovation, alignment of company and employee values, employee loyalty, and a culture of respect. The survey collected about 5,500 completed responses and evaluated firms on 24 characteristics.
The company highlighted its three-decade culture, scientific focus, and mission-driven workforce and directed readers to its careers page for more information.
Ionis (NASDAQ: IONS) announced that chief executive officer Brett P. Monia, Ph.D. will receive the 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS).
Monia, a founding member of OTS who joined Ionis in 1989 and became CEO in 2020, has led programs that produced multiple FDA‑approved oligonucleotide medicines and advanced more than 40 clinical programs across neurological, cardiometabolic and rare diseases. He has authored over 250 publications and holds more than 100 patents.
The award will be presented at the 21st Annual OTS Meeting in Budapest on October 21, 2025, where Ionis will also present preclinical and clinical research via oral and poster sessions.
Ionis (Nasdaq: IONS) will host a live webcast on Wednesday, October 29, 2025 at 11:30 a.m. Eastern Time to discuss third quarter 2025 financial results and progress on key programs.
Investors can access the live webcast and a limited-time replay at https://ir.ionis.com/events-and-presentations/upcoming-events. The company will cover Q3 2025 results and program updates during the presentation.